Axsome Therapeutics is trading 4.14% down at $159.13 on October 13, 2026, with no clear company-specific announcement identified to explain the intraday decline.
- The stock had closed lower for 12 consecutive sessions through October 12, while the S&P 500 gained 1.4% over that streak. The divergence points to stock-specific selling pressure.
- Biotech-sector weakness may add pressure; XBI was down 2.01%. Major indexes were only modestly lower, and identified coverage did not report a same-day volume figure.